Compare Organon & Co. Common Stock (OGN) vs Ondas Inc. Common Stock (ONDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Ondas Inc. Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Ondas Inc. Common Stock trades at $5.97 (market cap $3.90B). The key difference: Organon & Co. Common Stock and Ondas Inc. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Ondas Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Ondas Inc. Common Stock for 2 Days on average.
| OGN | ONDS | |
|---|---|---|
Market Cap | $3.62B | $3.90B |
Volume | 2,892,999 | 70,281,019 |
Sector | Health | Technology |
52-Week High | $13.81 | $14.01 |
52-Week Low | $5.70 | $5.25 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.04B | $2.53B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ONDS trades at $6.71, up 0.6% on the day, amid mixed technical signals with a bearish moving average trend but oversold RSI levels. The company reported a net loss of $132.02M for 2025 but shows a projected turnaround to $168M net profit for 2026. Recent developments include a strategic AI venture with Palantir and over $270M in new defense orders, boosting revenue visibility. Analyst sentiment is unanimously bullish with a consensus price target of $18.50.
The outlook for ONDS hinges on executing its growth strategy and achieving profitability targets. Investment opportunity lies in its expanding defense contracts and AI initiatives, but risks include persistent cash burn, high valuation multiples, and sector volatility. The stock presents a high-risk, high-reward profile dependent on successful operational execution and market adoption of its autonomous defense technologies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Ondas Inc. Common Stock
Ondas provides autonomous systems and private wireless solutions through its Ondas Autonomous Systems, Ondas Capital, and Ondas Networks business units. Its technologies combine aerial intelligence and next-generation connectivity for essential industries.
Read more on ONDS →
